2018-Jan-04
https://www.prnewswire.com/news-releases/cirius-therapeutics-expands-board-of-directors-with-appointment-of-dennis-m-fenton-300577392.html
Cirius Therapeutics Expands Board of Directors with Appointment of Dennis M. Fenton
NEWS PROVIDED BY Cirius Therapeutics 08:00 ET
KALAMAZOO, Mich. and SAN DIEGO, Jan. 4, 2018 /PRNewswire/ — Cirius Therapeutics, a clinical-stage pharmaceutical company focused on developing therapies to treat liver disease, announced today that Dennis Fenton, Ph.D., has been appointed to the company’s board of directors as an independent member.
“Having an industry veteran of Dennis’ caliber join our board adds considerable depth and breadth to our company’s stellar leadership team,” said Bob Baltera, chief executive officer of Cirius. “We expect Dennis’ wealth of industry expertise will be invaluable as we continue to advance our lead product candidate through a Phase 2b trial in NASH and plan for the next phase of growth.”
Dr. Fenton brings more than forty years of experience in biopharmaceutical drug development and commercialization to this position. During a 25-year tenure at Amgen, he served as executive vice president of operations and held numerous additional executive leadership roles in operations, process development, sales, marketing, research, engineering and manufacturing.
Since retiring from Amgen in 2008, Dr. Fenton has served as an independent biotechnology consultant and serves on several public and private company boards including Portola Pharmaceuticals, Pfenex, Sienna Biopharmaceuticals, Omniox, and Modern Meadow. Dr. Fenton previously served on the boards of directors of Kythera, Amira, Hospira, Dendreon Corp., Xenoport and Genzyme Corporation. He is also a member of the board of trustees of the Keck Graduate Institute. Dr. Fenton received a Bachelor of Science in Biology from Manhattan College and a Ph.D. in Microbiology from Rutgers University.
“I look forward to working with the board and management team at Cirius,” said Dr. Fenton. “NASH is a critical disease affecting millions of people and I welcome the opportunity to help make a difference for these individuals.”
# – # – # – # – #
Fenton, Dennis M. [MC1973]
# – # – # – # – # 2018-Jan-04 @ 12:32
COMMENT: McFadden, Michael J. (MC1973) “tubes everywhichwaybutup”
2017-Dec-10
John, your closure this week was well-stated: “Death is a natural process. And, ‘we’ have made it an expensive and terrible process. So sad.”
It is increasingly common for people to fill out “Living Wills” that specify what measures hospitals should take to prolong their lives. These directives focus mainly on intensive revival and sustaining of life at points where one would otherwise die very quickly. But perhaps more thought should be given to advance planning for when one is simply gravely ill and all medical indications are that, no matter what measures are taken as you are in intensive care with tubes everywhichwaybutup you are still about 99% certain not to see another year as you lie there or perhaps even another month or week. While it should certainly be an option to change one’s mind at such points, if one has previously thought about and discussed the option with family it’s possible that a good many people would say, “Just send me home, back to my own bedroom, with my loved ones near me in the place I’ve lived.”
It should certainly be a choice, and it’s an important enough choice that people should be encouraged to put some thought into it ahead of time.
McFadden, Michael J. (MC1973)
# – # – # – # – # 2017-Dec-10 @ 13:17
Leave a comment
Posted in COMMENT
Tagged MC1973